Danaher (DHR) Gears Up to Post Q2 Earnings: What to Expect

However, decreased demand in the bioprocessing business is likely to have hurt the Biotechnology segment’s revenues.

Zacks Jul 18 09:35 ET

Express News | Danaher Corp : JP Morgan Cuts Target Price to $295 From $300

ReutersJul 18 05:43 ET

Express News | Danaher Announced The Launch Of Two New Clinical Laboratory Improvement Amendments And College Of American Pathologists-certified Labs Intended To Accelerate The Development Of Companion Diagnostics And Complementary Diagnostics

BenzingaJul 17 07:37 ET

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA)

DanaherJul 17 00:00 ET

(DHR) - Analyzing Danaher's Short Interest

Danaher's (NYSE:DHR) short percent of float has risen 11.11% since its last report. The company recently reported that it has 8.61 million shares sold short, which is 1.3% of all regular shares that

BenzingaJul 16 15:30 ET

Danaher (DHR) Upgraded to Buy: Here's What You Should Know

Yahoo FinanceJul 16 12:00 ET